
Regardless of the number of manufacturers, generic drug prices presented double-digit average increases from 2012 to 2015.
Regardless of the number of manufacturers, generic drug prices presented double-digit average increases from 2012 to 2015.
Opioid use incidence and prevalence rates decreased with implementation of an opioid safety initiative, whereas nonsteroidal anti-inflammatory drug rates remained constant. Rates of adverse events were higher among opioid users.
From 2001 to 2011, the US Food and Drug Administration approved 9 single-enantiomer drugs with racemic precursors. None showed pre-approval evidence of improved efficacy over the racemic precursor.
After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.
Substantial variation in prescription spending and use of brand-name drugs exists across the VA healthcare system, with no apparent relationship to quality of care.
A higher proportion of veterans who use VA pharmacy services are black, have no alternative insurance, have lower incomes, are disabled, and report poorer health.
Published: August 18th 2025 | Updated: August 25th 2025
Published: August 19th 2025 | Updated: August 22nd 2025
Published: June 6th 2025 | Updated: August 18th 2025
Published: June 27th 2025 | Updated: July 1st 2025
Published: February 20th 2025 | Updated: February 21st 2025
Published: January 16th 2025 | Updated: January 29th 2025
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.